Uri Abadi
YOU?
Author Swipe
View article: The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma Open
Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome that complicates hematologic malignancies. The Optimized HLH Inflammatory (OHI) index, based solely on the combined elevation of soluble CD25 (sCD25; >3900 U/mL) a…
View article: Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study Open
Patients with relapsed/refractory diffuse large B-cell lymphoma progressing after chimeric antigen receptor T-cell (CAR-T) therapy have dismal outcomes. The prespecified post–CAR-T expansion cohort of the ELM-1 study investigated the effic…
View article: P651: REAL-WORLD EFFECTIVENESS OF VENETOCLAX-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN ISRAEL: UPDATE FROM THE MULTICENTER PROSPECTIVE REVEAL STUDY
P651: REAL-WORLD EFFECTIVENESS OF VENETOCLAX-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN ISRAEL: UPDATE FROM THE MULTICENTER PROSPECTIVE REVEAL STUDY Open
Background: The BCL-2 inhibitor venetoclax in combination with an anti-CD20 monoclonal antibody has demonstrated improved outcomes and manageable safety compared to chemo-immunotherapy in phase III clinical trials for chronic lymphocytic l…
View article: P1203: THE OPTIMIZED HLH INFLAMMATORY (OHI) INDEX IDENTIFIES LYMPHOMA PATIENTS WITH UNEXPECTEDLY HIGH MORTALITY NOT RELATED TO DISEASE PROGRESSION
P1203: THE OPTIMIZED HLH INFLAMMATORY (OHI) INDEX IDENTIFIES LYMPHOMA PATIENTS WITH UNEXPECTEDLY HIGH MORTALITY NOT RELATED TO DISEASE PROGRESSION Open
Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening inflammatory syndrome that may complicate hematologic malignancies (HM). We recently developed a simplified diagnostic and prognostic index termed the ‘optimized HL…
View article: αvβ3 Integrin Expression and Mitogenic Effects by Thyroid Hormones in Chronic Lymphocytic Leukemia
αvβ3 Integrin Expression and Mitogenic Effects by Thyroid Hormones in Chronic Lymphocytic Leukemia Open
Background: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. The thyroid hormones, T3 and T4, bind the αvβ3 integrin and activate phosphorylates ERK (pERK). These tumor-promoting actions were reported in a number of ma…
View article: PF325 REAL ‐ LIFE DATA ON ROMIDEPSIN TREATMENT FOR RELAPSED AND REFRACTORY PERIPHERAL AND CUTANEOUS T‐CELL LYMPHOMA ‐ A MULTICENTER NATIONAL OBSERVATIONAL STUDY
PF325 REAL ‐ LIFE DATA ON ROMIDEPSIN TREATMENT FOR RELAPSED AND REFRACTORY PERIPHERAL AND CUTANEOUS T‐CELL LYMPHOMA ‐ A MULTICENTER NATIONAL OBSERVATIONAL STUDY Open
Background: Peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) are uncommon subsets of non‐Hodgkin lymphomas (NHLs), comprising less than 15% of all NHLs. The rate of refractory and relapsed (R/R) disease remains high b…
View article: The induction of myeloma cell death and DNA damage by tetrac, a thyroid hormone derivative
The induction of myeloma cell death and DNA damage by tetrac, a thyroid hormone derivative Open
Multiple myeloma (MM) is a plasma cell malignancy in which involvement of the thyroid hormone-integrin αvβ3 pathway was shown, and pharmacologic inhibition of this pathway is a rational approach to disease management. A thyroid hormone der…
View article: Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim <scp>PET</scp>/<scp>CT</scp> is beneficial: a prospective multicentre trial of 355 patients
Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim <span>PET</span>/<span>CT</span> is beneficial: a prospective multicentre trial of 355 patients Open
Summary This multicentre study evaluated 5‐year progression‐free ( PFS ) and overall survival ( OS ) in early and advanced Hodgkin lymphoma ( HL ), where therapy was individualized based on initial prognostic factors and positron emission …